William Blair analyst Sarah Schram has maintained their bullish stance on DNLI stock, giving a Buy rating yesterday.
Sarah Schram’s rating is based on Denali Therapeutics’ strategic progress and promising clinical developments. The company is on track to submit a biologics license application for its treatment, Tivi, under the accelerated approval pathway by early 2025. This submission is bolstered by strong data from ongoing studies, which demonstrate significant efficacy and clinical benefits, particularly for Hunter syndrome patients.
Moreover, Denali’s proactive approach in preparing for the launch of Tivi, including engaging with providers and payers and building a commercial team, further supports the Buy rating. The breakthrough therapy designation for Tivi enhances the likelihood of a priority review, with potential market entry anticipated by late 2025 or early 2026. These factors collectively contribute to a positive outlook for the company’s stock.
Schram covers the Healthcare sector, focusing on stocks such as Denali Therapeutics, Xenon, and Alector. According to TipRanks, Schram has an average return of -2.1% and a 33.33% success rate on recommended stocks.